DUPILUMAB

Brand name:

• Dupixent®

Pharmaceutical company:

Sanofi-aventis Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Atopic dermatitis

PBAC Submission type:

New listing (Major)

Comment:

Medicine was reconsidered at the November 2020 PBAC

Public Summary Document:

PBAC Public Summary Documents – March 2020

Related medicines:

• DUPILUMAB
• DUPILUMAB

Submission received for:

March 2020 PBAC meeting

Opportunity for consumer comment:

Open 24/12/2019 and close 12/02/2020 (see PBS Website)

PBAC meeting:

Held on 11/03/2020

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

19/06/2020

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---